Breast cancer is one of the most prevalent and deadliest cancers among women in the world because of its aggressive behavior and inadequate response to conventional therapies. Cellular and gene therapies based on mesenchymal stem cells (MSCs) represent promising treatment strategies for multiple diseases, such as cancers. MSCs are multipotent adult stem cells with important features for cell therapy, such as tissue homing to injured sites, their differentiation potential, their capacity of secreting plenty of trophic factors, and low immunogenicity. The quite easy isolation of these cells from various types of tissues are associated with no ethical concern when dealing with fetal or embryonic stem cells. The MSCs exhibit both pro and anti-oncogenic properties. However, genetic engineering of MSCs and nanoparticles is being employed as a means to solve some of these problems and improve the antitumor properties of these cells. The tumor-homing ability of MSCs and their exosomes to tumor niches have made them as a promising vector for targeted delivery of therapeutic agents to tumors site. The present study investigated MSCs specifications, pro- and anti-oncogenic properties of MSCs in breast cancer, and reviewed targeted breast cancer therapy via engineered MSCs, likely as potent cellular vehicles.
This review discusses the application of nanoliposomes containing siRNA/drug to overcome multidrug resistance for all types of cancer treatments. As drug resistance-associated factors are overexpre... Graphical abstract
In this review, gene delivery and its applications are discussed in tissue engineering (TE); also, new techniques such as the CRISPR-Cas9 system, synthetics biology and molecular dynamics simulatio... TWEETABLE ABSTRACT Engineered cells and smart scaffolds for improving tissue engineering approaches. Graphical abstract
8 June 2026 in Journal of Polymers and the Environment
Background: Long non-coding ribonucleic acid (lncRNA) is known as similar transcripts of messenger RNA (mRNA) whose size discrepancy is between 100 and 200 nucleotides. Recent studies in this area have revealed that lncRNAs are involved in cancer tumorogenesis and progression. Such molecules are transcribed from genome regions that lack open reading frame (ORF) and fail to encode any protein. LncRNAs are characterized by tumorigenic behaviors which can be considered as new biomarkers. Among all types of thyroid cancer (TC), papillary thyroid carcinoma (PTC) is the most common one. Methods: This review was prepared via searching of the databases of Science Direct, Directory of Open Access Journals (DOAJ), Google Scholar, Pub-Med (NLM), Scopus, Web of Science, and hand searching using relative keywords. The selected papers were fully reviewed and required information for the review was extracted and summarized. Results: Pervious studies indicated that BRAF-activated non-protein coding RNA (BANCR) expression had been increased in thyroid tumors compared with adjacent normal tissues. Additionally, BANCR had mediated epithelial-mesenchymal transition (EMT) through regulating the expression of epithelial (E)-cadherin, vimentin, and neuronal (N)-cadherin. Moreover, H19 was an example of an lncRNA that could function either as a tumor promoter or suppressor. An important part of this study was dedicated to reviewing signaling pathways involved in TC including extracellular-signal-regulated kinase (ERK) pathway and mitogen-activated protein kinase (ERK/MAPK), transforming growth factor-β/ (TGF-ß)/Smads, the Janus kinase/signal transducers and activators of transcription (JAK/STAT), P53, as well as other pathways. Conclusion: Briefly, this study provided an overview on current understanding of the function of lncRNA and micro RNAs (miRNAs) along with their interactions in TC.